𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

✍ Scribed by Dominique Koensgen; Dirk Stengel; Antje Belau; Peter Klare; Guelten Oskay-Oezcelik; Thomas Steck; Oumar Camara; Alexander Mustea; Harald Sommer; Alexandra Coumbos; Thomas Bogenrieder; Werner Lichtenegger; Jalid Sehouli; on behalf of the NOGGO (North-Eastern German Society of Gynecological Oncology) Study Group Ovarian Cancer

Publisher
Springer
Year
2007
Tongue
English
Weight
324 KB
Volume
62
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sequential topotecan and oral etoposide
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane : Results from a multicenter Phase I/II study
✍ Bo Gronlund; Svend A. Engelholm; GyΓΆrgy Horvath; Johanna MΓ€enpÀÀ; Mona Ridderhei πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 100 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objectives of this study were to determine the maximum tolerable dose (MTD), toxicity, efficacy, and feasibility of a sequential regimen of fixed‐dose topotecan (1.00 mg/m^2^ on Days 1–5) and increasing doses of oral etoposide (50 mg, 75 mg, and 100 mg on Days 6–12 or

Phase II evaluation of three-day topotec
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study
✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 79 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a

A phase 1 and pharmacodynamic study of d
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 412 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c

Role of salvage chemotherapy with topote
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study
✍ Ghamande, Sharad A.; Piver, M. Steven πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 56 KB πŸ‘ 2 views

## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth